Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 676-682

  Rau, Kristi S ^a   Birdsall, Elisabeth ^a   Volz, Trent J ^a   Riordan, James A ^a   Baucum II, Anthony J ^a   Adair, Brian P ^a   Bitter, Rebecca ^a   Gibb, James W ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; CHLORAMPHETAMINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; METHAMPHETAMINE; METITEPINE; NORADRENALIN TRANSPORTER; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2; YOHIMBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE UPTAKE; HIPPOCAMPUS; MALE; NERVE ENDING; NONHUMAN; NORADRENERGIC NERVE; PRIORITY JOURNAL; RAT; SEROTONINERGIC NERVE CELL;

ANIMALS; BENZYLAMINES; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FLUOXETINE; MALE; METHAMPHETAMINE; NEURONS; P-CHLOROAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC VESICLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 33745961693     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.099200     Document Type: Article

References (40)

1. Axt KJ and Molliver ME (1991) Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse 9:302-313.
2. Bakhit C, Morgan ME, Peat MA, and Gibb JW (1981) Long-term effects of methamphetamine on synthesis and metabolism of 5-hydroxytryptamine in various regions of the rat brain. Neuropharmacology 20:1135-1140.
3. Breier JM, Bankson MG, and Yamamoto BK (2006) L-Tyrosine contributes to (+)3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin depletions. J Neurosci 26:290-299.
4. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
5. Eyerman DJ and Yamamoto BK (2005) Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312:160-169.
6. Finnegan KT, Ricaurte G, Seiden LS, and Schuster CR (1982) Altered sensitivity to d-methylamphetamine, apomorphine and haloperidol in rhesus monkeys depleted of caudate dopamine by repeated administration of d-methylamphetamine. Psychopharmacology 77:43-52.
7. Fleckenstein AE, Beyeler ML, Jackson JC, Wilkins DG, Gibb JW, and Hanson GR (1997a) Methamphetamine-induced decrease in tryptophan hydroxylase activity: role of 5-hydroxytryptaminergic transporters. Eur J Pharmacol 324:179-186.
8. Fleckenstein AE and Hanson GR (2003) Impact of psychostimulants on vesicular monoamine transporter function. Eur J Pharmacol 479:283-289.
9. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, and Hanson GR (1997b) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
10. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano K, Miller GW, and Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter-2 knock-out mice. J Neurosci 19:2424-2431.
11. Green AR, De Souza RJ, Williams JL, Murray TK, and Cross AJ (1992) The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: evidence for the protective effect of chlomethiazole. Neuropharmacology 31:315-321.
12. Hanson GR, Sandoval V, Riddle E, and Fleckenstein AE (2004) Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. Ann NY Acad Sci 1025:146-150.
13. Haughey HM, Fleckenstein AE, Metzger RR, and Hanson GR (2000) The effects of methamphetamine on serotonin transporter activity: role of dopamine and hyperthermia. J Neurochem 75:1608-1617.
14. Hogan KA, Staal RG, and Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-2220.
15. Hotchkiss AJ and Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase in rat brain. J Pharmacol Exp Ther 36:257-262.
16. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurements with Folin phenol reagent. J Biol Chem 193:265-275.
17. Meana JJ, Herrera-Marschitz M, Goiny M, and Silveira R (1997) Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain. Brain Res 744:216-226.
18. Morre MC and Wurtman RJ (1981) Characteristics of synaptosomal tyrosine uptake in various brain regions: effect of other amino acids. Life Sci 28:65-75.
19. Peter D, Jimenez J, Liu Y, Kim J, and Edwards RH (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 269:7231-7237.
20. Preston KL, Wagner GC, Schuster CR, and Seiden LS (1985) Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain. Brain Res 338:243-248.
21. Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, and Fleckenstein AE (2005) Bupropion increases striatal vesicular monoamine transport. Neuropharmacology 49:820-830.
22. Reith ME, Li MY, and Yan QS (1997) Extracellular dopamine, norepinephrine and serotonin in the ventral tegmental area and nucleus accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers. Psychopharmacology 134:309-317.
23. Ricaurte GA, Fuller RW, Perry KW, Seiden LS, and Schuster CR (1983) Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine. Neuropharmacology 22:1165-1169.
24. Riddle EL, Topham MK, Haycock JW, Hanson GR, and Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
25. Rocher C and Gardier AM (2001) Effects of repeated systemic administration of d-fenfluramine on serotonin and glutamate release in rat ventral hippocampus: comparison with methamphetamine using in vivo microdialysis. Naunyn-Schmiedeberg's Arch Pharmacol 363:422-428.
26. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, and Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synpase 39:32-41.
27. Sandoval V, Riddle EL, Hanson GR, and Fleckenstein AE (2002) Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 22:8705-8710.
28. Sandoval V, Riddle EL, Hanson GR, and Fleckenstein AE (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 304:1181-1187.
29. Schmidt CJ and Gibb JW (1985) Role of serotonin reuptake carrier in the neurochemical response to methamphetamine: effects of citalopram and chlorimipramine. Neurochem Res 10:637-648.
30. Schmidt CJ, Ritter JK, Sonsalla PK, Hanson GR, and Gibb JW (1985) Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther 233:539-544.
31. Seiden LS, Fischman MW, and Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219.
32. Seiden LS and Sabol KE (1995) Neurotoxicity of methamphetamine-related drugs and cocaine, in Handbook of Neurotoxicology (Chang LW and Dyer RS eds), pp 825-843, Marcel Dekker, New York.
33. Sulzer D and Rayport S (1990) Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron 5:797-808.
34. Sulzer D and Zecca L (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1:181-195.
35. 3H]dopamine uptake. J Pharmacol Exp Ther 280:1432-1444.
36. Truong JG, Hanson GR, and Fleckenstein AE (2004a) Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. Eur J Pharmacol 492:143-147.
37. Truong JG, Newman AH, Hanson GR, and Fleckenstein AE (2004b) Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur J Pharmacol 504:27-32.
38. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, and Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160.
39. Wagner GC, Seiden LS, and Schuster CR (1979) Methamphetamine induced changes in brain catecholamines in rats and guinea pigs. Drug Alcohol Depend 4:435-438.
40. Wrona MZ and Dryhurst G (2001) A putative metabolite of serotonin, tryptamine-4,5-dione, is an irreversible inhibitor of tryptophan hydroxylase: possible relevance to the serotonergic neurotoxicity of methamphetamine. Chem Res Toxicol 14:1184-1192.